IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019

IGF::OT::IGF 确定厄洛替尼联合舒林酸预防结直肠癌同时降低药物毒性的给药方案 POP 06/01/2017 - 05/31/2019

• 批准号: 9566448
• 负责人: POWEL BROWN
• 金额: $ 77.5万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-15 至 2019-06-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9566448
• 关键词: Adenomatous Polyposis Coli; Age; Animals; Clinical; Clinical Trials; Colonic Neoplasms; Colorectal Cancer; Coupled; Diet; Dose; Duodenum; Erlotinib; Ethnic Origin; Etiology; Gastrointestinal tract structure; Gender; Genetic; Geographic Locations; Growth; Individual; Inherited; Intestines; Long-Term Effects; Modeling; Non-Steroidal Anti-Inflammatory Agents; Operative Surgical Procedures; Patients; Pharmaceutical Preparations; Polyps; Prevention; Prevention strategy; Reducing Agents; Regimen; Resistance development; Risk; Schedule; Sulindac; Syndrome; Toxic effect; Treatment Efficacy; Treatment Protocols; adenoma; colorectal cancer prevention; improved; lifestyle factors; mortality; pharmacodynamic biomarker; polyposis; pre-clinical; predictive marker; standard of care; tumor

Mortality rates for colorectal cancer (CRC) vary according to geographic region, gender, age, ethnicity, and diet/lifestyle factors. Genetic influences also contribute to the etiology of CRC, for both sporadic cases and hereditary syndromes, such as familial adenomatous polyposis (FAP). Risk‐reducing surgical intervention in FAP patients often is coupled to prevention strategies using NSAIDs (nonsteroidal anti-inflammatory drugs). However, none of these agents is completely effective against adenoma growth in the GI tract, and Sulindac continues to be viewed as the standard of care in many clinical settings. Sulindac is effective in preclinical FAP models, including the Apc‐driven polyposis. Recent clinical trials (Samadder et al., JAMA 315:1266-1275, 2016) using a combination regimen of Sulindac administered twice/day with daily erlotinib for 6 months was shown to be effective in reducing the duodenal polyp burden in patients with FAP. However, the toxicity of the two drugs in combination may not allow long term treatment in a prevention setting. The purpose of this Task Order is to determine the optimal dosing and/or scheduling of erlotinib and Sulindac, individually and in combination, which reduce the toxicities associated with these drugs while maintaining or improving efficacy of the treatment regimens administered at animal equivalent dose levels; to determine the effects of the agents on tumor parameters in small intestinal compared to lower colonic tumors; to assess the effects of long term agent exposure on the potential to develop resistance; and assess pharmacodynamic markers predictive of agent efficacy.

结直肠癌（CRC）的死亡率因地理区域、性别、年龄、种族和饮食/生活方式等因素而异。对于散发性病例和遗传性综合征，如家族性腺瘤性息肉病（FAP），遗传影响也有助于CRC的病因学。FAP患者降低风险的手术干预通常与使用非甾体抗炎药（NSAIDs）的预防策略相结合。然而，这些药物中没有一种对胃肠道腺瘤生长完全有效，因此在许多临床环境中，舒林达仍然被视为标准治疗。舒林达克在临床前FAP模型中有效，包括Apc驱动的息肉病。最近的临床试验（Samadder等人，JAMA 315:1266-1275, 2016）显示，连续6个月使用舒林达/天两次与厄洛替尼每日联合用药可有效减轻FAP患者的十二指肠息肉负担。然而，两种药物联合使用的毒性可能不允许在预防设置中进行长期治疗。本任务令的目的是确定厄洛替尼和舒林达克的最佳剂量和/或计划，无论是单独使用还是联合使用，以减少与这些药物相关的毒性，同时保持或提高以动物等效剂量水平施用的治疗方案的疗效；目的：比较药物对小肠肿瘤参数的影响和对下结肠肿瘤参数的影响；评估长期接触药剂对产生耐药性的影响；并评估药物药效的药效学指标。